Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials

J. W. Kendig, R. H. Notter, C. Cox, Judy L. Aschner, S. Benn, R. M. Bernstein, K. Hendricks-Munoz, W. M. Maniscalco, L. A. Metlay, D. L. Phelps, R. A. Sinkin, B. P. Wood, D. L. Shapiro

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

A randomized trial of surfactant replacement therapy at birth was conducted at the University of Rochester between June 1983 and November 1985. Thirty-four premature infants, 25 to 29 weeks' gestational age, received a preventilatory dose of a calf lung surfactant extract in saline prepared at the University of Rochester. A control group of 31 infants received a preventilatory dose of saline alone. The major finding of this trial is that a single preventilatory dose of calf lung surfactant extract reduces the severity of the respiratory distress syndrome during the first 24 hours of life. The beneficial and diminish after 24 hours of life. The survival rate was 71% in both the control and surfactant-treated groups. There was a lower incidence of pneumothorax in the surfactant-treated group. There were no differences in the incidence of bronchopulmonary dysplasia, patent ductus arteriosus, and intraventricular hemorrhage. No adverse effects of surfactant replacement therapy were identified. Results of this study suggest that multiple post ventilatory doses of surfactant will be required for optimal therapy.

Original languageEnglish (US)
Pages (from-to)756-762
Number of pages7
JournalPediatrics
Volume82
Issue number5
StatePublished - 1988
Externally publishedYes

Fingerprint

Surface-Active Agents
Clinical Trials
Parturition
Therapeutics
Bronchopulmonary Dysplasia
Lung
Patent Ductus Arteriosus
Incidence
Pneumothorax
Premature Infants
Gestational Age
Hemorrhage
Control Groups

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Kendig, J. W., Notter, R. H., Cox, C., Aschner, J. L., Benn, S., Bernstein, R. M., ... Shapiro, D. L. (1988). Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials. Pediatrics, 82(5), 756-762.

Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials. / Kendig, J. W.; Notter, R. H.; Cox, C.; Aschner, Judy L.; Benn, S.; Bernstein, R. M.; Hendricks-Munoz, K.; Maniscalco, W. M.; Metlay, L. A.; Phelps, D. L.; Sinkin, R. A.; Wood, B. P.; Shapiro, D. L.

In: Pediatrics, Vol. 82, No. 5, 1988, p. 756-762.

Research output: Contribution to journalArticle

Kendig, JW, Notter, RH, Cox, C, Aschner, JL, Benn, S, Bernstein, RM, Hendricks-Munoz, K, Maniscalco, WM, Metlay, LA, Phelps, DL, Sinkin, RA, Wood, BP & Shapiro, DL 1988, 'Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials', Pediatrics, vol. 82, no. 5, pp. 756-762.
Kendig, J. W. ; Notter, R. H. ; Cox, C. ; Aschner, Judy L. ; Benn, S. ; Bernstein, R. M. ; Hendricks-Munoz, K. ; Maniscalco, W. M. ; Metlay, L. A. ; Phelps, D. L. ; Sinkin, R. A. ; Wood, B. P. ; Shapiro, D. L. / Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials. In: Pediatrics. 1988 ; Vol. 82, No. 5. pp. 756-762.
@article{056efa64d3fc45869762abf154bf4e3e,
title = "Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials",
abstract = "A randomized trial of surfactant replacement therapy at birth was conducted at the University of Rochester between June 1983 and November 1985. Thirty-four premature infants, 25 to 29 weeks' gestational age, received a preventilatory dose of a calf lung surfactant extract in saline prepared at the University of Rochester. A control group of 31 infants received a preventilatory dose of saline alone. The major finding of this trial is that a single preventilatory dose of calf lung surfactant extract reduces the severity of the respiratory distress syndrome during the first 24 hours of life. The beneficial and diminish after 24 hours of life. The survival rate was 71{\%} in both the control and surfactant-treated groups. There was a lower incidence of pneumothorax in the surfactant-treated group. There were no differences in the incidence of bronchopulmonary dysplasia, patent ductus arteriosus, and intraventricular hemorrhage. No adverse effects of surfactant replacement therapy were identified. Results of this study suggest that multiple post ventilatory doses of surfactant will be required for optimal therapy.",
author = "Kendig, {J. W.} and Notter, {R. H.} and C. Cox and Aschner, {Judy L.} and S. Benn and Bernstein, {R. M.} and K. Hendricks-Munoz and Maniscalco, {W. M.} and Metlay, {L. A.} and Phelps, {D. L.} and Sinkin, {R. A.} and Wood, {B. P.} and Shapiro, {D. L.}",
year = "1988",
language = "English (US)",
volume = "82",
pages = "756--762",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Surfactant replacement therapy at birth final analysis of a clinical trial and comparisons with similar trials

AU - Kendig, J. W.

AU - Notter, R. H.

AU - Cox, C.

AU - Aschner, Judy L.

AU - Benn, S.

AU - Bernstein, R. M.

AU - Hendricks-Munoz, K.

AU - Maniscalco, W. M.

AU - Metlay, L. A.

AU - Phelps, D. L.

AU - Sinkin, R. A.

AU - Wood, B. P.

AU - Shapiro, D. L.

PY - 1988

Y1 - 1988

N2 - A randomized trial of surfactant replacement therapy at birth was conducted at the University of Rochester between June 1983 and November 1985. Thirty-four premature infants, 25 to 29 weeks' gestational age, received a preventilatory dose of a calf lung surfactant extract in saline prepared at the University of Rochester. A control group of 31 infants received a preventilatory dose of saline alone. The major finding of this trial is that a single preventilatory dose of calf lung surfactant extract reduces the severity of the respiratory distress syndrome during the first 24 hours of life. The beneficial and diminish after 24 hours of life. The survival rate was 71% in both the control and surfactant-treated groups. There was a lower incidence of pneumothorax in the surfactant-treated group. There were no differences in the incidence of bronchopulmonary dysplasia, patent ductus arteriosus, and intraventricular hemorrhage. No adverse effects of surfactant replacement therapy were identified. Results of this study suggest that multiple post ventilatory doses of surfactant will be required for optimal therapy.

AB - A randomized trial of surfactant replacement therapy at birth was conducted at the University of Rochester between June 1983 and November 1985. Thirty-four premature infants, 25 to 29 weeks' gestational age, received a preventilatory dose of a calf lung surfactant extract in saline prepared at the University of Rochester. A control group of 31 infants received a preventilatory dose of saline alone. The major finding of this trial is that a single preventilatory dose of calf lung surfactant extract reduces the severity of the respiratory distress syndrome during the first 24 hours of life. The beneficial and diminish after 24 hours of life. The survival rate was 71% in both the control and surfactant-treated groups. There was a lower incidence of pneumothorax in the surfactant-treated group. There were no differences in the incidence of bronchopulmonary dysplasia, patent ductus arteriosus, and intraventricular hemorrhage. No adverse effects of surfactant replacement therapy were identified. Results of this study suggest that multiple post ventilatory doses of surfactant will be required for optimal therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023701504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023701504&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 756

EP - 762

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -